RESET-SLE (CABA-201, NCT06121297) meets its Week-52 drug-free DORIS-remission efficacy endpoint in the lupus nephritis cohort.

55% likely to miss · raimo

target CD19 · moa CD19 CAR-T deep transient B-cell depletion enabling immune reset

1. premise Academic autologous CD19 CAR-T in autoimmune disease produced DORIS remission in all SLE patients with complete withdrawal of immunosuppression, durable over follow-up. pmid:38381673
2. premise The commercial product rese-cel (CABA-201) is replicating this: 7 of 8 lupus patients with sufficient follow-up reached DORIS or renal response as of ACR October 2025. url:cabaletta-acr-2025
3. inference Deep transient B-cell depletion re-establishes a stable non-autoreactive state, a durable drug-free reset, which is the mechanism this endpoint measures. This is human mechanism evidence a genetics-plus-class-prior model underweights. pmid:38381673
4. premise Offsetting downside: the lupus-nephritis cohort is harder than nonrenal SLE, the Week-52 drug-free DORIS bar is stringent, and a new preconditioning-free lower-dose cohort may deplete less deeply.
5. prediction RESET-SLE meets its Week-52 drug-free DORIS remission endpoint in the lupus-nephritis cohort with probability 0.45, materially above the ~0.22 genetics-plus-class-prior estimate.

Evidence: pmid:38381673, url:cabaletta-acr-2025